Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
RenJi Hospital
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05926726CT.gov GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05120271CT.gov BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04506983CT.gov GPC3-CAR-T Cells for the Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT06144385CT.gov A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03884751CT.gov Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT03980288CT.gov 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT03302403CT.gov Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | — | Unknown | — | — | — |
NCT03146234CT.gov CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| gpc3-car-t cells (this asset) | RenJi Hospital | P1/2 | CCC · 53 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for gpc3-car-t cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myxoid/Round Cell Liposarcoma | — | P1/2 | CCC · 48 |
| Squamous Cell Lung Carcinoma | — | P1/2 | CCC · 48 |
| Cutaneous Neuroendocrine Carcinoma | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. gpc3-car-t cells in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gpc3-car-t-cells-hepatocellular-carcinoma-102640
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →